Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. Clin Infect Dis (2015) 3.83

Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol Cell (2014) 2.83

Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol (2014) 2.75

An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J Am Soc Nephrol (2016) 1.49

Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study. Circulation (2015) 1.42

RNAi therapies: drugging the undruggable. Sci Transl Med (2014) 1.26

Imaging and nanomedicine in inflammatory atherosclerosis. Sci Transl Med (2014) 1.23

Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet (2015) 1.19

Activating frataxin expression by repeat-targeted nucleic acids. Nat Commun (2016) 1.17

Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med (2015) 1.13

siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids (2015) 1.12

Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther (2013) 1.11

Current progress on aptamer-targeted oligonucleotide therapeutics. Ther Deliv (2013) 1.09

Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener (2014) 1.07

Macrophages retain hematopoietic stem cells in the spleen via VCAM-1. J Exp Med (2015) 1.06

Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. Mol Ther Nucleic Acids (2013) 1.05

Alnylam's RNAi therapy targets amyloid disease. Nat Biotechnol (2015) 1.03

Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov (2015) 1.02

Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov (2015) 1.02

Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev (2015) 1.01

Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat Biotechnol (2015) 1.01

Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol (2014) 1.00

Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure. Circ Res (2016) 0.99

Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics (2014) 0.98

Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol (2015) 0.98

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. Mol Ther (2015) 0.98

In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain (2014) 0.96

RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proc Natl Acad Sci U S A (2014) 0.95

Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol (2013) 0.95

The bright side of dark matter: lncRNAs in cancer. J Clin Invest (2016) 0.94

Clinical Translation of Nanomedicine. Chem Rev (2015) 0.93

Progress in material design for biomedical applications. Proc Natl Acad Sci U S A (2015) 0.90

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol (2016) 0.90

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev (2015) 0.89

Exploiting endocytosis for nanomedicines. Cold Spring Harb Perspect Biol (2013) 0.89

Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure. J Community Hosp Intern Med Perspect (2014) 0.88

Translating MicroRNA Biology in Pulmonary Hypertension: It Will Take More Than "miR" Words. Am J Respir Crit Care Med (2016) 0.87

High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides. Nucleic Acids Res (2015) 0.86

Genome editing in cardiovascular diseases. Nat Rev Cardiol (2016) 0.86

Exosome-mediated Delivery of Hydrophobically Modified siRNA for Huntingtin mRNA Silencing. Mol Ther (2016) 0.85

Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy. Mol Ther Nucleic Acids (2014) 0.84

The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel) (2016) 0.84

Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase. Biochim Biophys Acta (2015) 0.84

Cellular uptake and intracellular trafficking of oligonucleotides. Adv Drug Deliv Rev (2015) 0.83

A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis. Neurol Ther (2015) 0.83

Infiltrative Cardiomyopathies. Clin Med Insights Cardiol (2015) 0.83

Bioconjugates for targeted delivery of therapeutic oligonucleotides. Adv Drug Deliv Rev (2015) 0.83

Current and future treatment of amyloid diseases. J Intern Med (2016) 0.83

Modified mRNA Vaccines Protect against Zika Virus Infection. Cell (2017) 0.83

Current understanding of interactions between nanoparticles and the immune system. Toxicol Appl Pharmacol (2015) 0.82

Dendrimer-Inspired Nanomaterials for the in Vivo Delivery of siRNA to Lung Vasculature. Nano Lett (2015) 0.82

Uncovering the Mechanism of Aggregation of Human Transthyretin. J Biol Chem (2015) 0.82

Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid (2016) 0.82

Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer. Oncotarget (2015) 0.82

Ionizable amphiphilic dendrimer-based nanomaterials with alkyl-chain-substituted amines for tunable siRNA delivery to the liver endothelium in vivo. Angew Chem Int Ed Engl (2014) 0.82

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis (2015) 0.82

Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform. Cancer Gene Ther (2014) 0.82

MicroRNAs in heart failure: Small molecules with major impact. Glob Cardiol Sci Pract (2014) 0.82

Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry. Transplantation (2016) 0.81

D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. Nat Commun (2016) 0.81

Physiological IgM class catalytic antibodies selective for transthyretin amyloid. J Biol Chem (2014) 0.81

Tissue-specific gene silencing monitored in circulating RNA. RNA (2013) 0.81

Systemic Administration of siRNA via cRGD-containing Peptide. Sci Rep (2015) 0.81

DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat Commun (2015) 0.81

Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses. Mol Ther (2015) 0.80

Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification. Mol Ther Nucleic Acids (2015) 0.80

Evolving landscape in the management of transthyretin amyloidosis. Ann Med (2015) 0.80

Modulating inhibitors of transthyretin fibrillogenesis via sulfation: polychlorinated biphenyl sulfates as models. Chem Biol Interact (2015) 0.80

Technologies for controlled, local delivery of siRNA. J Control Release (2015) 0.80

Imaging-guided delivery of RNAi for anticancer treatment. Adv Drug Deliv Rev (2016) 0.79

MiRNA inhibition in tissue engineering and regenerative medicine. Adv Drug Deliv Rev (2014) 0.79

DNA Nanotechnology for Cancer Therapy. Theranostics (2016) 0.78

Small-nucleic-acid-based therapeutic strategy targeting the transcription factors regulating the vascular inflammation, remodeling and fibrosis in atherosclerosis. Int J Mol Sci (2015) 0.78

Conjugation of palmitic acid improves potency and longevity of siRNA delivered via endosomolytic polymer nanoparticles. J Biomed Mater Res A (2015) 0.78

Harnessing human ADAR2 for RNA repair - Recoding a PINK1 mutation rescues mitophagy. Nucleic Acids Res (2016) 0.78

Co-fibrillogenesis of Wild-type and D76N β2-Microglobulin: THE CRUCIAL ROLE OF FIBRILLAR SEEDS. J Biol Chem (2016) 0.78

Targeting microRNAs for immunomodulation. Curr Opin Pharmacol (2015) 0.78

Short-interference RNAs: becoming medicines. EXCLI J (2015) 0.78

Identification of siRNA delivery enhancers by a chemical library screen. Nucleic Acids Res (2015) 0.78

Onset Time and Durability of Huntingtin Suppression in Rhesus Putamen After Direct Infusion of Antihuntingtin siRNA. Mol Ther Nucleic Acids (2015) 0.78

Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside. Int J Nanomedicine (2016) 0.78

A pliable electroporation patch (ep-Patch) for efficient delivery of nucleic acid molecules into animal tissues with irregular surface shapes. Sci Rep (2015) 0.78

The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol (2017) 0.77

Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol Ther (2017) 0.77

Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes. Mol Ther (2017) 0.77

Bifunctional crosslinking ligands for transthyretin. Open Biol (2015) 0.77

Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers. Mol Ther (2016) 0.77

Effects of an antisense oligonucleotide inhibitor of C-reactive protein synthesis on the endotoxin challenge response in healthy human male volunteers. J Am Heart Assoc (2014) 0.77

Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol (2014) 0.77

Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol (2016) 0.77

Multistage Delivery Technologies: Multifunctional, Interdisciplinary Approaches to Nanomedicine. Mol Ther (2016) 0.77

The Genetic Challenges and Opportunities in Advanced Heart Failure. Can J Cardiol (2015) 0.77

The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response. PLoS One (2015) 0.77

Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development: Implications for the Treatment of Vein Graft Failure. Arterioscler Thromb Vasc Biol (2015) 0.77

Current siRNA targets in atherosclerosis and aortic aneurysm. Discov Med (2014) 0.77

Lipid Nanoparticle-mediated siRNA Transfer Against PCTAIRE1/PCTK1/Cdk16 Inhibits In Vivo Cancer Growth. Mol Ther Nucleic Acids (2016) 0.76

Structural Analysis of Human Argonaute-2 Bound to a Modified siRNA Guide. J Am Chem Soc (2016) 0.76

Hydrophobic interactions between polymeric carrier and palmitic acid-conjugated siRNA improve PEGylated polyplex stability and enhance in vivo pharmacokinetics and tumor gene silencing. Biomaterials (2016) 0.76

RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver. J Hepatol (2015) 0.76

Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid (2016) 0.76

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55

From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature (2010) 12.07

Annotation of the Drosophila melanogaster euchromatic genome: a systematic review. Genome Biol (2002) 8.59

Comparative genome sequencing of Drosophila pseudoobscura: chromosomal, gene, and cis-element evolution. Genome Res (2005) 8.38

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64

Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19

Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57

Natural history and outcome in systemic AA amyloidosis. N Engl J Med (2007) 4.54

Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med (2002) 4.47

RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol (2006) 4.38

Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A (2010) 4.25

T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging (2013) 4.21

Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med (2012) 3.99

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev (2010) 3.99

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med (2003) 3.86

Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging (2013) 3.53

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48

Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35

American Society of Echocardiography recommendations for quality echocardiography laboratory operations. J Am Soc Echocardiogr (2011) 3.32

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther (2010) 3.26

BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24

The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases. Genet Med (2011) 3.14

Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med (2012) 3.14

Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol (2007) 3.12

Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol (2012) 3.09

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88

Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol (2013) 2.81

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74

Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov (2010) 2.68

Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med (2010) 2.62

Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum (2002) 2.58

Evolution of proteins and gene expression levels are coupled in Drosophila and are independently associated with mRNA abundance, protein length, and number of protein-protein interactions. Mol Biol Evol (2005) 2.42

Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther (2009) 2.39

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol (2004) 2.37

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34

Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med (2004) 2.32

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. J Neurosci (2004) 2.29

Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26

Retracted A BLOC-1 mutation screen reveals that PLDN is mutated in Hermansky-Pudlak Syndrome type 9. Am J Hum Genet (2011) 2.25

Dynorphin A activates bradykinin receptors to maintain neuropathic pain. Nat Neurosci (2006) 2.23

Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20

Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum (2002) 2.19

A status report on RNAi therapeutics. Silence (2010) 2.18

Nonacid reflux in patients with chronic cough on acid-suppressive therapy. Chest (2006) 2.14

Multiple actions of systemic artemin in experimental neuropathy. Nat Med (2003) 2.12

Low-dose acetazolamide reverses periventricular white matter hyperintensities in iNPH. Neurology (2014) 2.08

Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res (2007) 2.06

Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson (2008) 2.01

Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci (2003) 1.95

RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med (2010) 1.94

An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. Blood (2012) 1.94

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A (2010) 1.92

Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91

Silencing of lipid metabolism genes through IRE1α-mediated mRNA decay lowers plasma lipids in mice. Cell Metab (2012) 1.90

Detecting false-positive signals in exome sequencing. Hum Mutat (2012) 1.87

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood (2012) 1.80

The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab (2012) 1.79

Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood (2012) 1.64

American Society of Echocardiography: Remote Echocardiography with Web-Based Assessments for Referrals at a Distance (ASE-REWARD) Study. J Am Soc Echocardiogr (2013) 1.62

Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2008) 1.61

Estimating sympathetic tone by recording subcutaneous nerve activity in ambulatory dogs. J Cardiovasc Electrophysiol (2014) 1.61

RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother (2009) 1.60

Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart (2012) 1.56

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol (2013) 1.54

Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases. PLoS Genet (2011) 1.54

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood (2006) 1.54